Details

Autor(en) / Beteiligte

• Pizzutilo, Elio Gregory
• Agostara, Alberto Giuseppe
• Roazzi, Laura
• Romanò, Rebecca
• Motta, Valentina
• Lauricella, Calogero
• Marrapese, Giovanna
• Cerea, Giulio
• Signorelli, Diego
• Veronese, Silvio Marco
• Giannetta, Laura Giuseppina
• Sartore-Bianchi, Andrea
• Siena, Salvatore

Titel

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report

Ist Teil von

• JTO clinical and research reports, 2023-11, Vol.4 (11), p.100555, Article 100555

Ort / Verlag

Elsevier

Erscheinungsjahr

2023

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds are under clinical development. ROS1 F2004 substitutions have been previously detected on circulating tumor DNA of patients progressing to entrectinib. Hereby, we report the case of a patient with ROS1+ NSCLC in which F2004V-acquired mutation was detected on a site of disease progression, after entrectinib and crizotinib failure. A subsequent treatment with next-generation TKI repotrectinib led to disease response, providing the first clinical evidence of activity of repotrectinib against F2004V resistance mutation.